ANEB Key Statistics, Chart & Performance
The current stock price of ANEB is 1.07 USD. In the past month the price decreased by -10.08%. In the past year, price decreased by -30.52%.
ANEB Technical Analysis
ANEB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ANEB. ANEB has a great financial health rating, but its profitability evaluates not so good.
ANEB Financial Highlights
Over the last trailing twelve months ANEB reported a non-GAAP Earnings per Share(EPS) of -0.23. The EPS increased by 23.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.86% | ||
| ROE | -72.78% | ||
| Debt/Equity | 0 |
ANEB Forecast & Estimates
6 analysts have analysed ANEB and the average price target is 8.16 USD. This implies a price increase of 662.62% is expected in the next year compared to the current price of 1.07.
ANEB Ownership
About ANEB
Company Profile
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the provision of pharmaceutical services. The company is headquartered in Lakeway, Texas and currently employs 2 full-time employees. The company went IPO on 2021-05-07. The company is engaged in developing treatments for cannabis toxicity, such as unintentional cannabis poisoning, acute cannabinoid intoxication (ACI) and the landscape of acute cannabis-induced conditions. Its lead product candidate is selonabant, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat cannabis toxicity. Selonabant is orally bioavailable, rapidly absorbed, and has also been formulated for intravenous administration. Selonabant is intended to rapidly reverse the negative effects of cannabis-induced toxicity and reduce time to recovery. The company is also prioritizing the advancement of a selonabant intravenous (IV) formulation as a potential treatment for pediatric patients with cannabis-induced CNS depression.
Company Info
ANEBULO PHARMACEUTICALS INC
C/O Anebulo Pharmaceuticals, Inc., 1017 Ranch Road 620 South, Suite 107
Lakeway TEXAS US
CEO: Daniel Schneeberger
Employees: 2
Phone: 17372035270
ANEBULO PHARMACEUTICALS INC / ANEB FAQ
What does ANEBULO PHARMACEUTICALS INC do?
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the provision of pharmaceutical services. The company is headquartered in Lakeway, Texas and currently employs 2 full-time employees. The company went IPO on 2021-05-07. The company is engaged in developing treatments for cannabis toxicity, such as unintentional cannabis poisoning, acute cannabinoid intoxication (ACI) and the landscape of acute cannabis-induced conditions. Its lead product candidate is selonabant, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat cannabis toxicity. Selonabant is orally bioavailable, rapidly absorbed, and has also been formulated for intravenous administration. Selonabant is intended to rapidly reverse the negative effects of cannabis-induced toxicity and reduce time to recovery. The company is also prioritizing the advancement of a selonabant intravenous (IV) formulation as a potential treatment for pediatric patients with cannabis-induced CNS depression.
Can you provide the latest stock price for ANEBULO PHARMACEUTICALS INC?
The current stock price of ANEB is 1.07 USD. The price decreased by -2.73% in the last trading session.
Does ANEB stock pay dividends?
ANEB does not pay a dividend.
What is the ChartMill technical and fundamental rating of ANEB stock?
ANEB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the market capitalization of ANEB stock?
ANEBULO PHARMACEUTICALS INC (ANEB) has a market capitalization of 43.96M USD. This makes ANEB a Nano Cap stock.
What is the ownership structure of ANEBULO PHARMACEUTICALS INC (ANEB)?
You can find the ownership structure of ANEBULO PHARMACEUTICALS INC (ANEB) on the Ownership tab.
What is the outstanding short interest for ANEBULO PHARMACEUTICALS INC?
The outstanding short interest for ANEBULO PHARMACEUTICALS INC (ANEB) is 0.28% of its float.